Cargando…

Tolerance to alternative cyclooxygenase-2 inhibitors in nonsteroidal anti-inflammatory drug hypersensitive patients

BACKGROUND: Non-steroidal anti-inflammatory drugs (NSAIDs) frequently cause adverse drug reactions. Many studies have shown that drugs which selectively inhibit the cyclooxygenase-2 enzyme (COX-2) are safe alternatives in the majority of patients. However, hypersensitivity reactions to COX-2 inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Malskat, Wendy SJ, Knulst, André C, Bruijnzeel-Koomen, Carla AFM, Röckmann, Heike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3704733/
https://www.ncbi.nlm.nih.gov/pubmed/23799898
http://dx.doi.org/10.1186/2045-7022-3-20
_version_ 1782476325318033408
author Malskat, Wendy SJ
Knulst, André C
Bruijnzeel-Koomen, Carla AFM
Röckmann, Heike
author_facet Malskat, Wendy SJ
Knulst, André C
Bruijnzeel-Koomen, Carla AFM
Röckmann, Heike
author_sort Malskat, Wendy SJ
collection PubMed
description BACKGROUND: Non-steroidal anti-inflammatory drugs (NSAIDs) frequently cause adverse drug reactions. Many studies have shown that drugs which selectively inhibit the cyclooxygenase-2 enzyme (COX-2) are safe alternatives in the majority of patients. However, hypersensitivity reactions to COX-2 inhibitors have been published. Hardly any data are available regarding the safety of alternatives in case of COX-2 inhibitor hypersensitivity. We aimed to investigate the tolerance to COX-2 inhibitors in patients with non-selective NSAID hypersensitivity. Furthermore, in COX-2 hypersensitive patients tolerance of a second COX-2 inhibitor was investigated. METHODS: We retrospectively analyzed 91 patients with proven non-selective NSAID hypersensitivity that underwent oral challenges with a COX-2 inhibitor. Patients with intolerance to the first challenged COX-2 inhibitor received a second challenge with a different COX-2 inhibitor. RESULTS: 19 out of 91 (21%) patients had a positive reaction to the first oral challenge with a COX-2 inhibitor. 14 of them underwent a second challenge with a different COX-2 inhibitor and 12 (86%) did not react. CONCLUSIONS: A relatively high percentage (21%) of the non-selective NSAID hypersensitive patients did not tolerate a COX-2 inhibitor and oral challenge is advised prior to prescription of a COX-2 inhibitor. For the majority of patients reacting to a COX-2 inhibitor an alternative can be found.
format Online
Article
Text
id pubmed-3704733
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-37047332013-07-10 Tolerance to alternative cyclooxygenase-2 inhibitors in nonsteroidal anti-inflammatory drug hypersensitive patients Malskat, Wendy SJ Knulst, André C Bruijnzeel-Koomen, Carla AFM Röckmann, Heike Clin Transl Allergy Research BACKGROUND: Non-steroidal anti-inflammatory drugs (NSAIDs) frequently cause adverse drug reactions. Many studies have shown that drugs which selectively inhibit the cyclooxygenase-2 enzyme (COX-2) are safe alternatives in the majority of patients. However, hypersensitivity reactions to COX-2 inhibitors have been published. Hardly any data are available regarding the safety of alternatives in case of COX-2 inhibitor hypersensitivity. We aimed to investigate the tolerance to COX-2 inhibitors in patients with non-selective NSAID hypersensitivity. Furthermore, in COX-2 hypersensitive patients tolerance of a second COX-2 inhibitor was investigated. METHODS: We retrospectively analyzed 91 patients with proven non-selective NSAID hypersensitivity that underwent oral challenges with a COX-2 inhibitor. Patients with intolerance to the first challenged COX-2 inhibitor received a second challenge with a different COX-2 inhibitor. RESULTS: 19 out of 91 (21%) patients had a positive reaction to the first oral challenge with a COX-2 inhibitor. 14 of them underwent a second challenge with a different COX-2 inhibitor and 12 (86%) did not react. CONCLUSIONS: A relatively high percentage (21%) of the non-selective NSAID hypersensitive patients did not tolerate a COX-2 inhibitor and oral challenge is advised prior to prescription of a COX-2 inhibitor. For the majority of patients reacting to a COX-2 inhibitor an alternative can be found. BioMed Central 2013-06-24 /pmc/articles/PMC3704733/ /pubmed/23799898 http://dx.doi.org/10.1186/2045-7022-3-20 Text en Copyright © 2013 Malskat et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Malskat, Wendy SJ
Knulst, André C
Bruijnzeel-Koomen, Carla AFM
Röckmann, Heike
Tolerance to alternative cyclooxygenase-2 inhibitors in nonsteroidal anti-inflammatory drug hypersensitive patients
title Tolerance to alternative cyclooxygenase-2 inhibitors in nonsteroidal anti-inflammatory drug hypersensitive patients
title_full Tolerance to alternative cyclooxygenase-2 inhibitors in nonsteroidal anti-inflammatory drug hypersensitive patients
title_fullStr Tolerance to alternative cyclooxygenase-2 inhibitors in nonsteroidal anti-inflammatory drug hypersensitive patients
title_full_unstemmed Tolerance to alternative cyclooxygenase-2 inhibitors in nonsteroidal anti-inflammatory drug hypersensitive patients
title_short Tolerance to alternative cyclooxygenase-2 inhibitors in nonsteroidal anti-inflammatory drug hypersensitive patients
title_sort tolerance to alternative cyclooxygenase-2 inhibitors in nonsteroidal anti-inflammatory drug hypersensitive patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3704733/
https://www.ncbi.nlm.nih.gov/pubmed/23799898
http://dx.doi.org/10.1186/2045-7022-3-20
work_keys_str_mv AT malskatwendysj tolerancetoalternativecyclooxygenase2inhibitorsinnonsteroidalantiinflammatorydrughypersensitivepatients
AT knulstandrec tolerancetoalternativecyclooxygenase2inhibitorsinnonsteroidalantiinflammatorydrughypersensitivepatients
AT bruijnzeelkoomencarlaafm tolerancetoalternativecyclooxygenase2inhibitorsinnonsteroidalantiinflammatorydrughypersensitivepatients
AT rockmannheike tolerancetoalternativecyclooxygenase2inhibitorsinnonsteroidalantiinflammatorydrughypersensitivepatients